Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbsland recall

This article was originally published in The Tan Sheet

Executive Summary

All 100-tablet bottles of Ancom Anti-Hypertensive Compound Tablets recalled by Herbsland because they contain several Rx drug ingredients, including reserpine, diazepam, promethiazine, company says Jan. 17. Product is "unapproved new drug" and "poses possible serious health risks including sedation, depression and potentially life-threatening abnormalities of the blood," 1Herbsland press release says, although no adverse events have been reported. Sold through distributors, retail stores in the New York metropolitan area and over the Internet, Ancom tablets are labeled for anti-hypertensive use and come in white plastic bottles with an outer cardboard holding carton. Manufacturer is listed as Chinese firm Shanghai Pharmaceutical Industry...

You may also be interested in...

Ancom recall

Availability of Ancom Anti-Hypertensive Compound Tablets has caused one adverse event so far, FDA says March 17. Tai Chien is recalling all 100-count bottles of the product because they contain several Rx ingredients, including diazepam, promethiazine, reserpine, which may pose health risks such as "sedation, depression and potentially life-threatening abnormalities of the blood," agency notes. Herbsland recalled same product in January (1"The Tan Sheet" Jan. 20, 2003, p. 8). Tablets are manufactured by Shanghai Pharmaceutical, sold at retail stories in New York City, online...

EU MDR Notified Body Designations Could Soar By A Third By End Of 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.

Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts